基亞 (3176.TWO)

43.25 +0.15 (+0.35%) 收市：01:30PM CST

基亞

No.3, Park Street
14th Floor Nangang District
Taipei 11503
Taiwan
886 2 7736 1234
https://www.medigen.com.tw

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Shun-Lang Chang	General Manager	9.81M	無	無
Ms. Ya-Ling Chiang	Assistant Vice President of Operations & Management Department	3.04M	無	無
Ms. Chin-Yen Chen	Assistant Vice President of Drug Development Department	2.54M	無	無
Ms. Feng-Hua Chen	Finance Manager	無	無	無
Ms. I-Ju Chen	Accounting Manager	無	無	無
Mr. Chieh-Liang Lin	Chief Scientific Officer	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 TWD。

描述

Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for esophageal cancer and gastric cancer patients in the United States. Medigen Biotechnology Corp. was founded in 1999 and is headquartered in Taipei, Taiwan.

公司管治

截至 無 止，基亞 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。